

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Denosumab for the treatment of bone metastases from solid tumours and multiple myeloma

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Amgen (denosumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • African and Caribbean Leukaemia Trust (ACLT) • Anthony Nolan Bone Marrow Trust • Black Health Agency • CANCERactive • Cancer Black Care • Cancer 52 • Cancer Equality • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Leonard Cheshire Disability • Leukaemia CARE • Leukaemia & Lymphoma Research • Leukaemia Society (UK) • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Myeloma UK • Muslim Council of Britain • Muslim Health Network • RADAR - Royal Association for Disability & Rehabilitation • Rarer Cancers Foundation • Skill: National Bureau for Students with Disabilities • South Asian Health Foundation • Specialised Healthcare Alliance 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Services • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • Public Health Wales NHS Trust • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Bayer Schering (disodium clodronate) • Beacon Pharmaceuticals (disodium clodronate) • Hospira UK (disodium pamidronate) • Medac UK (disodium pamidronate) • Novartis (disodium pamidronate, zoledronic acid) • Roche (disodium clodronate, ibandronic acid) • Wockhardt (disodium pamidronate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Institute of Cancer Research • MRC Clinical Trials Unit

National Institute for Health and Clinical Excellence

Consultation on the provisional matrix for the appraisal of denosumab for the treatment of bone metastases from solid tumours and multiple myeloma

Issue date: December 2010

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Sue Ryder Care • Tenovus • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Association of Surgical Oncology (BASO) • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Institute of Radiology • British Oncological Association (BOA) • British Orthopaedic Association • British Orthopaedic Oncology Society • British Psychosocial Oncology Society • British Society for Haematology • British Society of Rehabilitation Medicine • British Society of Skeletal Radiologists • British Uro-Oncology Group • Cancer Networks Pharmacists Forum • Cancer Research UK • National Osteoporosis Society (NOS) • Pelican Cancer Foundation • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Myeloma Forum 	<ul style="list-style-type: none"> • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • United Kingdom Clinical Research Network <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Peninsula Technology Assessment Group, University of Exeter (PenTAG) • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

National Institute for Health and Clinical Excellence

Consultation on the provisional matrix for the appraisal of denosumab for the treatment of bone metastases from solid tumours and multiple myeloma

Issue date: December 2010

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Sheffield PCT • Welsh Assembly Government • West Sussex Teaching PCT 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).